Clinical trials
Lupus Nephritis clinical trials
Below are recruiting lupus nephritis clinical trials, each written for real people, not researchers. We’re tracking 82 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06631404Recruiting
Ultrasound test for lupus kidney activity
This trial uses an ultrasound to measure kidney blood flow in people with lupus kidney disease. The goal is to see if this simple test can tell how active the disease is, which might help doctors adjust treatment without needing frequent biopsies.
SohagAges 18–50 - NCT06904729RecruitingPhase 3
CAR-T cell therapy for tough lupus kidney disease in children
This trial tests a new type of immune cell therapy (CAR-T cells) for children whose lupus kidney disease (lupus nephritis) has not responded to standard treatments. The CAR-T cells are designed to target and remove certain immune cells that are attacking the kidneys, with the goal of stopping the disease.
Guangzhou, GuangdongAges 6–18 - NCT06927219Recruiting
Lupus registry for patients and caregivers
This study creates a registry for people with lupus and their families. It helps researchers learn more about lupus and improve care. You or your child can join if you have a lupus diagnosis.
Washington D.C., District of ColumbiaAges Any age - NCT06682507Recruiting
Lupus nephritis long-term study
This study follows patients with lupus nephritis (kidney inflammation caused by lupus) over time to learn more about the disease and improve care. You may join if you have had a kidney biopsy confirming lupus nephritis at this hospital.
Guangzhou, GuangdongAges 14 years+ - NCT05934149Recruiting
Lupus health registry that stores samples for future research
This study keeps a long-term record of people with lupus (systemic lupus erythematosus) and collects samples so researchers can study the disease better. You may be able to join if you meet lupus diagnosis criteria, are not pregnant, and can follow the study visits and consent process.
Birmingham, AlabamaAges 18–110 - NCT06491602Recruiting
Lupus nephritis in children at Sohag Hospital
This study looks at children with lupus nephritis (a kidney problem caused by lupus) to understand what factors affect their disease and outcomes. It may help doctors better treat kids with this condition.
SohagAges 1 month–18 years - NCT04702256RecruitingPhase 3
Treating lupus kidney inflammation with or without extra steroid tablets
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
ParisAges 14 years+ - NCT07760480RecruitingPhase 4
Intensified treatment for lupus nephritis
This study tests whether adding a drug called voclosporin to the usual treatment for lupus nephritis (a kidney disease caused by lupus) can better reduce kidney inflammation. It also looks at the role of immune cells in this process.
AmsterdamAges 16–70 - NCT07719140RecruitingPhase 4
Lower steroid dose study for children with lupus nephritis
This trial tests whether a lower starting dose of steroids can control kidney inflammation in children with lupus nephritis. It aims to reduce side effects while still treating the disease effectively.
Beijing, Beijing MunicipalityAges 6–18 - NCT05538208RecruitingPhase 2
Children with lupus kidney inflammation using mycophenolate
This Phase 2 study tests how well the medicine mycophenolate mofetil (MMF) works for children and teens with lupus nephritis that is “proliferative” (a specific biopsy type). You may qualify if your kidney biopsy and current treatment match the study’s targets and you can follow frequent visits and testing.
San Francisco, CaliforniaAges 8–20 - NCT06711887RecruitingPhase 3
Long-term extension study of ianalumab for lupus nephritis
This study is a follow-up for people with lupus nephritis who already completed a 144-week treatment course with ianalumab in an earlier study. It tests whether continuing or stopping the drug is safe and effective over the long term.
Orchard Park, New YorkAges 18–100 - NCT07340463RecruitingPhase 2
Biologics vs standard therapy for lupus kidney disease
This trial tests two biologic drugs (belimumab or telitacicept) compared to a standard treatment (mycophenolate mofetil) for people with active lupus nephritis. The goal is to see if biologics work better at controlling kidney inflammation over 6 months.
Nanjing, JiangsuAges 14–65 - NCT05268289RecruitingPhase 2
Trial for lupus kidney inflammation using LNP023
This Phase 2 study tests whether LNP023 can improve outcomes and safety in people with active lupus nephritis (lupus-related kidney inflammation), class III or IV. It may help by targeting the ongoing immune activity that is damaging the kidneys.
Phoenix, ArizonaAges 18–100 - NCT06155604RecruitingPhase 2
SGLT2 inhibitor for lupus nephritis with kidney disease
This study tests if an SGLT2 inhibitor can help protect kidney function in people who have lupus nephritis (kidney inflammation caused by lupus) and chronic kidney disease (CKD). The goal is to see if this medicine can slow down further kidney damage.
Hong KongAges 18 years+ - NCT06167174Recruiting
Looking for markers to predict lupus kidney treatment response
This study is looking for biomarkers (clues in your blood, urine, or tissue) that can help predict how well lupus nephritis (kidney inflammation caused by lupus) responds to treatment. It focuses on people who have active kidney disease and are either starting treatment or have been on a stable treatment for at least a month.
BeijingAges 16–60 - NCT06497361RecruitingEarly Phase 1
PRG-2311 for hard-to-treat lupus nephritis and IgG4 disease
This trial tests a new treatment called PRG-2311 for people with lupus nephritis or IgG4-related disease that has not responded to standard therapies. The treatment uses a type of immune cell therapy (CAR-T) to try to control the disease.
Wuhan, HubeiAges 18 years+ - NCT06497387RecruitingEarly Phase 1
PRG-1801 for stubborn lupus kidney and IgG4 disease
This trial tests a new treatment called PRG-1801 for people with lupus nephritis (kidney inflammation from lupus) or IgG4-related disease that has not improved with standard treatments. The treatment uses your own immune cells to target and calm the disease.
Wuhan, HubeiAges 18 years+ - NCT06434363RecruitingPhase 1/Phase 2
Cell therapy plus tafasitamab for autoimmune diseases
This trial tests a new cell therapy (AD-PluReceptor) combined with the drug tafasitamab for people with certain autoimmune diseases like systemic sclerosis, lupus, or chronic graft-versus-host disease. It aims to see if this treatment can help when standard therapies have failed.
Houston, TexasAges 18 years+ - NCT06642402Recruiting
Studying lupus kidney disease using urine particles
This study looks at tiny particles in urine to better understand and monitor lupus-related kidney problems. It may help find better ways to track the disease without invasive biopsies.
KoldingAges 18 years+ - NCT07491900RecruitingPhase 1
Study of HB2198 for lupus with moderate to severe symptoms
This trial tests a new drug called HB2198 to see if it can help people with moderate to severe lupus. It may be an option for those whose current treatments haven't worked well enough.
BrisbaneAges 18–65 - NCT07017868Recruiting
Uric acid and other blood markers in lupus kidney disease
This study looks at whether certain substances in the blood, such as uric acid, homocysteine, and interleukin-17, are higher in people with lupus-related kidney disease compared to healthy individuals. It aims to find new ways to monitor or understand the condition better.
SohagAges 18 years+ - NCT07629583RecruitingPhase 1
Testing cevostamab for lupus with kidney involvement
This study tests a new drug called cevostamab for people with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body's own tissues. Some participants also have lupus nephritis, which means the disease is affecting their kidneys. The drug may help by targeting a specific part of the immune system.
SevilleAges 18–75 - NCT05916781RecruitingPhase 4
Lowering steroids with mycophenolate and tacrolimus for lupus kidneys
This study tests whether using mycophenolate mofetil plus tacrolimus can help people with lupus nephritis safely lower (taper) their prednisone to a low dose. It is designed for people whose kidney lupus has been well-controlled for at least 6 months.
BeijingAges 18–65 - NCT06121297RecruitingPhase 1/Phase 2
CABA-201 for active lupus
This trial tests a new treatment called CABA-201, which is a type of immune cell therapy (CAR T cells) for people with active lupus. The goal is to see if it's safe and can help control lupus symptoms.
Orange, CaliforniaAges 18–65
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus nephritis?
- Yes. Clin2 currently lists 82 recruiting lupus nephritis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus nephritis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus nephritis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.